Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial.

Michael Staehler; Michael Stöckle; Daniel C Christoph; Arnulf Stenzl; Karin Potthoff; Marc-Oliver Grimm; Dunja Klein; Johanna Harde; Fabian Brüning; Peter J Goebell; Marinela Augustin; Frederik Roos; Iris Benz-Rüd; Norbert Marschner; Viktor Grünwald

doi:10.1002/ijc.33349

Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial.

Michael Staehler
, Michael Stöckle
, Daniel C Christoph
, Arnulf Stenzl
, Karin Potthoff
, Marc-Oliver Grimm
, Dunja Klein
, Johanna Harde
, Fabian Brüning
, Peter J Goebell
, Marinela Augustin (Co-Autor/-in)
, Frederik Roos
, Iris Benz-Rüd
, Norbert Marschner
, Viktor Grünwald

Universitätsklinik für Innere Medizin 5 - Onkologie und Hämatologie

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

5 Quellenangaben (Web of Science)

Originalsprache	Englisch
Seiten (von - bis)	1685-1694
Fachzeitschrift	INTERNATIONAL JOURNAL OF CANCER
Jahrgang	148
Ausgabenummer	7
DOIs	https://doi.org/10.1002/ijc.33349
Publikationsstatus	Veröffentlicht - 2021

Zugriff auf Dokument

10.1002/ijc.33349

Dieses zitieren

Staehler, M., Stöckle, M., Christoph, D. C., Stenzl, A., Potthoff, K., Grimm, M.-O., Klein, D., Harde, J., Brüning, F., Goebell, P. J., Augustin, M., Roos, F., Benz-Rüd, I., Marschner, N., & Grünwald, V. (2021). Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial. INTERNATIONAL JOURNAL OF CANCER, 148(7), 1685-1694. https://doi.org/10.1002/ijc.33349

@article{d3c212bb5e364206ae4bebfb3b9c05c9,

title = "Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial.",

keywords = "CLINICAL-PRACTICE GUIDELINES, PREDICTIVE FACTORS, 2ND-LINE THERAPY, OPEN-LABEL, SORAFENIB, SUNITINIB, EFFICACY, DIAGNOSIS",

author = "Michael Staehler and Michael St{\"o}ckle and Christoph, \{Daniel C\} and Arnulf Stenzl and Karin Potthoff and Marc-Oliver Grimm and Dunja Klein and Johanna Harde and Fabian Br{\"u}ning and Goebell, \{Peter J\} and Marinela Augustin and Frederik Roos and Iris Benz-R{\"u}d and Norbert Marschner and Viktor Gr{\"u}nwald",

note = "Augustin: Paracelsus Med Univ, Klinikum Nuremberg, Dept Hematol *** Oncol, Nurnberg, Germany; ",

year = "2021",

doi = "10.1002/ijc.33349",

language = "English",

volume = "148",

pages = "1685--1694",

journal = "INTERNATIONAL JOURNAL OF CANCER",

issn = "0020-7136",

publisher = "Wiley Verlag ",

number = "7",

}

Staehler, M, Stöckle, M, Christoph, DC, Stenzl, A, Potthoff, K, Grimm, M-O, Klein, D, Harde, J, Brüning, F, Goebell, PJ, Augustin, M, Roos, F, Benz-Rüd, I, Marschner, N & Grünwald, V 2021, 'Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial.', INTERNATIONAL JOURNAL OF CANCER, Jg. 148, Nr. 7, S. 1685-1694. https://doi.org/10.1002/ijc.33349

TY - JOUR

T1 - Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial.

AU - Staehler, Michael

AU - Stöckle, Michael

AU - Christoph, Daniel C

AU - Stenzl, Arnulf

AU - Potthoff, Karin

AU - Grimm, Marc-Oliver

AU - Klein, Dunja

AU - Harde, Johanna

AU - Brüning, Fabian

AU - Goebell, Peter J

AU - Augustin, Marinela

AU - Roos, Frederik

AU - Benz-Rüd, Iris

AU - Marschner, Norbert

AU - Grünwald, Viktor

N1 - Augustin: Paracelsus Med Univ, Klinikum Nuremberg, Dept Hematol *** Oncol, Nurnberg, Germany;

PY - 2021

Y1 - 2021

KW - CLINICAL-PRACTICE GUIDELINES

KW - PREDICTIVE FACTORS

KW - 2ND-LINE THERAPY

KW - OPEN-LABEL

KW - SORAFENIB

KW - SUNITINIB

KW - EFFICACY

KW - DIAGNOSIS

U2 - 10.1002/ijc.33349

DO - 10.1002/ijc.33349

M3 - Original Article

C2 - 33070307

SN - 0020-7136

VL - 148

SP - 1685

EP - 1694

JO - INTERNATIONAL JOURNAL OF CANCER

JF - INTERNATIONAL JOURNAL OF CANCER

IS - 7

ER -